UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.

Caribou Biosciences, a US-based cell therapy developer spun out of University of California, Berkeley is going public today in a $304m initial public offering. The company increased the number of shares in the offering from 17 million to 19 million and priced them at the top of the IPO’s $14 to $16 range. It is…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.